IŞIL

Prof. Dr. Işıl Somalı, M.D.

Oncology Surgeon

Işıl Somalı, MD is a respected physician with extensive experience in the fields of Internal Medicine and Medical Oncology. After completing his primary and secondary education in Izmir, he graduated from Ege University Faculty of Medicine in 1994. In the same year, he started his specialization training at Dokuz Eylül University Faculty of Medicine, Department of Internal Medicine, and after his Internal Medicine specialization training, he worked as a Medical Oncology assistant at the Oncology Institute of the same university. He completed his branch specialization training in 2002. In 2003, he started working as the first Medical Oncology Specialist at Izmir Atatürk Training and Research Hospital and played a fundamental role in the establishment and development of the Medical Oncology Department there.

After becoming an Associate Professor in 2010, he started working as an Associate Professor at Dokuz Eylül University Oncology Institute in 2011, and received the title of Professor in 2015. He started working at Egepol Hospital in 2022. It offers effective solutions to the health problems of its patients without ignoring human values in the treatment and follow-up processes. He is a physician who always prioritizes the health and well-being of his patients and constantly updates his knowledge in this field.

Apart from patient treatment processes, he has made significant contributions to the training of many Internal Medicine and Medical Oncology specialists in the institutions where he works. He has many academic articles published domestically and abroad and has served as the principal investigator in international clinical studies.

Courses – Certificates

  • Izmir Uğur Yıkmaz Oncology Days 7th Rare Tumors Symposium Optimal Neutropenia
  • What Should the Method Be? To Attend the Themed Meeting Online, Izmir, February 2021 (Being an Invited Speaker)
  • Specialization Student Thesis Jury To Participate as a Jury Member in Dr. Ragıp Fatih Kural’s Examination, İzmir, January 2021 (Jury Member in the Master’s Thesis Defense)
  • Changing Algorithms in Hormone Positive Breast Cancer Current
  • Questions Meeting Izmir, December 2020 (Invited Speaker)
  • To Attend the Meeting on Ribociclib and Turkey Experience in HR+Her2 negative Metastatic Breast Cancer, Izmir, October 2020 (Invited Speaker)
  • Current Developments Before Chemotherapy in Metastatic Castration-
  • Resistant Prostate Cancer, Izmir, October 2020(Invited Speaker)
  • Target Cancer 2020 About to Participate, TRNC, March 2020 (President, organizer and invited speaker as a member of the Organizing Board and Executive Board)
  • HR+Her2- Current Developments in Metastatic Breast Cancer and Abemaciclib Clinical Data
  • Meeting, Izmir, February 2020 (Being an Invited Speaker)
    To Participate in the 3rd Oncology Perspective Congress with Young People, Antalya, February 2020 (Session
    Serving as President)
  • To Attend the Meeting on Lung Cancer Current Treatment Approaches, Izmir,
  • February 2020(Being an Invited Speaker)
    “9 Th International Gastrointestinal Cancer Conference”, Istanbul,
  • December 2019 (Serving as Session Chair)”
    “Second-Line Treatment of Metastatic Non-Small Cell Lung Cancer with Cases”
    Izmir, December 2019(Being an Invited Speaker)
  • “Metastatic Colorectal Cancer Case Consultancy Assignment”, İzmir, November 2019 (Other)”
  • Themed “The Power Is Now in Your Hands with Valamor in Hormone Receptor Positive Breast Cancer”, Izmir, November 2019(Other)
  • “3. To Participate in the “National Immunotherapy and Oncology Congress”, Antalya, November 2019 (Serving as Session Chair)
  • Assignment to Participate in the “3rd National Urogenital Cancers Congress”, TRNC, October 2019 (Serving as Session Chair)
  • “Inter-Clinical Metastatic Colon Cancer Update Meeting”, İzmir, October 2019 (Invited Speaker)
  • “3. To Participate in “Muğla Multidisciplinary Oncological Research Congress”, Muğla, October 2019 (Serving as Session Chair)
  • ” To Participate in the Associate Professor Oral Examination as a Jury Member, Istanbul, October 2019 (Other)
  • To Participate in the “ESO 2019” Assignment, Spain, September 2019 (As an impressionist – participant in the scientific event)
  • “6. To Participate in “Black Sea Oncology Days”, Trabzon, September 2019 (Serving as Session Chair)
  • “Current Developments Related to Tumor Location in Metastatic Colorectal Cancer Treatment”, İzmir, June 2019 (Invited Speaker)
  • To Participate in the Assignment Themed “Breast Cancer with Problem Based Learning”, İzmir, May 2019 (Invited Speaker)
  • The Place of Palbociclib in Current Treatment, Izmir, May 2019 (Invited Speaker)
  • “23. National Cancer Congress”, Antalya, April 2019 (Serving as Session Chair)
  • Target Cancer 2019 About to Attend, TRNC, April 2019 (Being a Panelist)
    “Targeted Treatment Approaches in Metastatic Soft Tissue Sarcomas and Metastatic Sarcoma Subtypes Meeting”, İzmir, April 2019(Other)
  • To Attend the 2nd Eskişehir Oncology Days, Eskişehir, April 2019 (Serving as Session Chair)
  • Associate Professor Oral Exam, Istanbul, January 2019 (Jury Membership in the Associate Professor Exam)
  • “Targeted Treatment Approaches and Case Sharing Meeting in Metastatic Malignant Melenomen”, İzmir, December 2018 (Invited Speaker)
  • “Developments in Breast Cancer Treatment from Past to Present”, İzmir, December 2018 (Invited Speaker)
  • To Attend the “Advanced Board Advisory Board Meeting”, Istanbul, December 2018 (Other)
  • To Participate in the “8th International Gastrointestinal Cancer Conference” Assignment, Istanbul, December 2018 (Serving as Session Chair)
  • “Current Approaches in Second-Line Treatment of Both Positive Metastatic Breast Cancer” İzmir, November 2018 (Invited Speaker)
  • “3. To Attend the “Geriatric Oncology Congress”, Antalya, November 2018 (Serving as Session Chair)
  • “2nd National Immunotherapy and Oncology Congress”, Antalya, November 2018 (Serving as Session Chair)
  • ESMO 2018/ Congress. Germany, October 2018(As an impressionist -participant in the scientific event)
  • ” VIII. “National Lung Cancer Congress”, Muğla, October 2018 (As an impressionist – participant in the scientific event)
  • “19th World Conference On Lung Cancer” Assignment, Canada, September 2018 (As an impressionist – participant in the scientific event)
  • ” 2018 Tekirdağ Oncology Symposium”, Tekirdağ, September 2018 (Serving as Session Chair)
  • “Shares with Cases in Hormonal Treatment of Breast Cancer”, İzmir, September 2018 (Invited Speaker)
  • “Immunology Journey with Cases”, İzmir, May 2018(Other)
  • “Current Developments in Metastatic Colorectal Cancer Treatment”, April 2018 (Invited Speaker)
  • ” Target Cancer 2018 ”, TRNC, April 2018 (Serving as Session Chair)
    “Pertuzumab in All 2 Positive Early Stage Breast Cancers”,
  • Izmir, March 2018(Being an Invited Speaker)
    “Current Approaches in Second-Line Treatments for Her 2 (+) Metastatic Breast Cancer”, İzmir, March 2018 (Invited Speaker)
  • “7. Turkish Medical Oncology Congress”, Antalya, March 2018 (Invited Speaker)
  • “Current Developments in the Treatment of Metastatic Colorectal Cancer”, İzmir, November 2017 (Invited Speaker)
  • Cetuximab Treatment with Cases in Metastatic Colorectal Cancer” İzmir, November 2017 (Invited Speaker)
  • To Attend the National Immunotherapy and Oncology Congress, Antalya, October 2017 (Serving as Session Chair)
  • To Attend the 14th National Breast Diseases Congress, Antalya, October 2017 (Invited Speaker)
  • About to Attend The IASLC 18 Th World Conference On Lung Cancer, Japan, October 2017 (As an impressionist – participant in the scientific event)
  • Associate Professor Oral Exam, Istanbul, October 2017 (Associate Professor exam commission member)
  • To Participate in the Assignment Themed “Targeted Agents in Melanoma Treatment”, Izmir, June 2017 (Invited Speaker)
  • To Attend the Workshop on Is 40 Months and More Survival Possible in Metastatic Colorectal Cancer Treatment,
    Izmir, May 2017(Being an Invited Speaker)
    “one. About to Attend Eskişehir Oncology Days, Eskişehir, May 2017 (Invited Speaker)
  • “15 Th St.Gallen International Breast Cancer Conference Primary Therapy of Early Breast
    Cancer Viena”, Austria, March 2017(As an impressionist – participant in the scientific event)
  • To Attend the Meeting on Approach to ALK+ and ROS+ Patients in Metastatic Non-Small Cell Lung Cancer, Izmir, February 2017 (Invited Speaker)
  • To Attend the “Scientific Qualification Meeting for Medical Promotion Representatives”
    Assignment., Istanbul, January 2017(Other)
  • To Attend the “Metastatic Breast Cancer Treatment Consensus Meeting”, Izmir, December 2016 (Invited Speaker)
    “one. Assigned to Participate in the “National Oncology Congress with Cases”, Antalya, December 2016 (Invited Speaker)
  • To Participate in the “6 Th International Gastrointestinal Cancer Conference” Assignment, Antalya, December 2016 (Invited Speaker)
  • “Pamukkale Oncology Days”, Denizli, November 2016 (Invited Speaker)
    To Attend the Meeting titled Awareness and Place of Pertuzumab in the
  • Treatment of Her2 Positive Metastatic Breast Cancer, Izmir, November 2016 (Invited Speaker)
  • “5. Quests in Oncology Symposium, Izmir, November 2016 (Editor as Member of the Organizing Board)
  • “2nd Geriatric Oncology Congress” Antalya, October 2016 (Session Chair)
    To Participate in “ESMO 2016 Congress” as an Impressionist Participant, Copenhagen, Denmark, October 2016
  • ” XI. To Participate in the “Current Therapies in Clinical Oncology Symposium”, Aydın, May 2016 (Session Chair)
  • “3rd National Immuno-Oncology and Targeted Cancer Therapies Congress”, Antalya, May 2016 (Impressionist – participant in the scientific event)
  • “Current Approaches in Metastatic Renal Cell Cancer Treatment”, Izmir, April 2016 (Notification / Paper Presentation (Poster, Oral, etc.))
    To Participate in the “Target Cancer 2016” Assignment, TRNC, April 2016 (Panel Moderation)
  • To Participate in the “6th Turkish Medical Oncology Congress”, Antalya, March 2016 (Invited Speaker
  • “Her 2 Targeted Adjuvant Treatment Algorithms in Her 2 Positive and Lymph Node Negative Early Stage Breast Cancer”, İzmir, March 2016 (Invited Speaker)
  • To Participate in the Assignment on “Effectiveness and Treatment Management in MRI Treatment, İzmir, March 2016 (Being an Invited Speaker)
  • “11th National Oncological Research Workshop”, Antalya, November 2015 (Being a Panelist)
  • To Attend the Meeting on “Targeted Treatment in NSCLC Patients”, Izmir, November 2015 (Invited Speaker)
  • To Participate in the “Current Developments in Metastatic Colorectal Cancer Treatment” Assignment, İzmir, October 2015 (Invited Speaker)
    To Participate in the “1st Geriatric Oncology Symposium”, Ankara, October 2015 (Invited Speaker)
  • To Participate in the “ESMO World Congress On Gastrointestinal Cancer 2015” Assignment, Spain, July 2015 (Notification / Paper Presentation (Poster, Oral, etc.))
  • To Attend “Dokuz Eylül University Mentor Meeting”, İzmir, June 2015 (Invited Speaker)
  • To Attend the X. Aydın Oncology Days, Aydın, May 2015 (Session Chairperson)
  • To Participate in the 2nd Immuno-Oncology and Targeted Therapies Congress, Antalya, May 2015 (As an impressionist – participant in the scientific event)
  • “21. To Attend the “National Cancer Congress”, Antalya, April 2015 (Being an Invited Speaker)
  • “Her 2 + The Importance of Continuous Suppression of Her 2 in Breast Cancer” Izmir, March 2015 (Invited Speaker)
  • To Participate in the 10th National Oncological Research Workshop Congress, Antalya, November 2014 (Invited Speaker)
  • To Attend the 1st Geriatric Oncology Congress, Antalya, October 2014 (Invited Speaker)
  • To Participate in the “Promotion Work for Medical Promotion Representatives”, Izmir, September 2014 (Invited Speaker)
  • “To Participate in the Specialization Education Graduation Exam at Adnan Menderes University as a Jury Member”, Aydın, April 2014 (Jury Member in the Master’s Thesis defense)

International Publications

  • Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
    Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, Iwata H, Gnant M, Loibl S, Barrios CH, Somali I, Smichkoska S, Martinez N, Alonso MG, Link JS, Mayer IA, Cold S , Murillo SM, Senecal F, Inoue K, Ruiz-Borrego M, Hui R, Denduluri N, Patt D, Rugo HS, Johnston SRD, Bryce R, Zhang B, Xu F, Wong A, Martin M; ExteNET Study Group.
    Clin Breast Cancer. 2021 Feb;21(1):80-91.e7. doi: 10.1016/j.clbc.2020.09.014. Epub 2020 Oct 6.
    PMID: 33183970 Clinical Trial.
  • Early thrombocytopenia predicts longer time‑to‑treatment discontinuation in trastuzumab emtansine treatment.
    Sahin AB, Caner B, Ocak B, Gulmez A, Hamitoglu B, Cubukcu E, Deligonul A, Orhan SO, Canhoroz M, Odman HU, Somali I, Ocakoglu G, Evrensel T.
    Oncol Lett. 2023 Oct 23;26(6):523. doi: 10.3892/ol.2023.14110. eCollection 2023 Dec.
    PMID: 37927419 Free PMC article.
  • The prognostic role of thyroid transcription factor-1 in lung adenocarcinoma.
    Oktay E, Oflazoglu U, Varol Y, Tanriverdi O, Mermur N, Arda HU, Demir L, Keskin O, Ahmadli T, Somali I, Oztop I, Meydan N.
    J Cancer Res Ther. 2020 Jul-Sep;16(4):737-744. doi: 10.4103/jcrt.JCRT_1404_16.
    PMID: 32930112
    The prognostic role of epidermal growth factor receptor mutation in completely resected ampullary adenocarcinoma.
    Varol U, Cakır E, Aktas S, Altun ZS, Dilek FH, Butun O, Salman T, Unlu AGD, Alacacioglu A, Somali I.
    Pol J Pathol. 2023;74(1):18-28. doi: 10.5114/pjp.2023.127044.
    PMID: 37306349
  • Prevalence of Gastrointestinal Symptoms and Clinical Outcomes in Hospitalized Coronavirus Disease 2019 Patients: A Single-Center Study from Turkey.
    Dolu S, Bengi G, Avkan-Oğuz V, Tertemiz KC, Gezer NS, Çavuş SA, Alpaydın AÖ, Kuruüzüm Z, Ergan B, Sevinç C, Ömeroğlu Şimsek G, Kılınç O, Örmen M, Sayıner A, Somalı I, Çavdar C , Can G, Demir T, Akarsu M, Savran Y, Soytürk M.
    Turk J Gastroenterol. 2022 Nov;33(11):955-963. doi: 10.5152/tjg.2022.21484.
    PMID: 35946895 Free PMC article.
  • Evaluation of hereditary/familial breast cancer patients with multigene targeted next generation sequencing panel and MLPA analysis in Turkey.
    Bora E, Caglayan AO, Koc A, Cankaya T, Ozkalayci H, Kocabey M, Kemer D, Aksoy S, Alicikus ZA, Akin IB, Durak MG, Gurel D, Yavuzsen T, Sevinc A, Somali I, Gorken I, Balci P , Karaoglu A, Saydam S, Ulgenalp A.
    Cancer Genet. 2022 Apr;262-263:118-133. doi: 10.1016/j.cancergen.2022.02.006. Epub 2022 Feb 16.
    PMID: 35220195
  • Tumoral and Parenchymal Morphological Assessment in Liver Metastases of Colorectal Carcinoma: Micrometastasis, Peritumoral Lymphocytes, Tumor Budding and Differentiation are Potential Prognostic Factors.
    Aysal A, Agalar C, Egeli T, Ozbilgin M, Unek T, Somali I, Oztop I, Obuz F, Astarcioglu I, Sagol O.
    Int J Surg Pathol. 2022 Dec;30(8):861-871. doi: 10.1177/10668969221095459. Epub 2022 May 2.
    PMID: 35491669